<DOC>
	<DOCNO>NCT00806624</DOCNO>
	<brief_summary>This study conduct male female subject age 18 80 year , inclusive , non-valvular AF CHADS2 Score least 1 . Subjects treat outpatient basis . The subject allocate randomly open-label warfarin double-blind DU-176b dosage . DU-176b administer orally 12 week two fixed dos . Warfarin use active control . Warfarin dose manage monitor Investigator dose adjust achieve INR 2.0 3.0 , inclusive . The primary endpoint incidence major , clinically relevant non-major minor bleeding event ( bleed ) .</brief_summary>
	<brief_title>DU-176b Phase 2 Dose Finding Study Subjects With Non-valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Male female subject 18 80 year age Nonvalvular AF support abnormal ECG document two time ( interval 1 week ) within 6 month prior randomization . CHADS2 Score least 1 . Subjects mitral valve disease Subjects previous valvular heart surgery Contraindication anticoagulant Conditions associate high risk bleed Acute coronary syndrome ( ACS ) , percutaneous coronary intervention ( PCI ) , MI , stroke , transient ischemic attack ( TIA ) coronary artery/cardiac/other major surgery within previous 30 day Active infective endocarditis lifeexpectancy &lt; 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>